Association between Cytochrome P450 2D6 Genotype and Harm Avoidance

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 127 B, Issue 1, 2004, Pages 90-93

  Roberts, Rebecca L ^a   Luty, Suzanne E ^a   Mulder, Roger T ^a   Joyce, Peter R ^a   Kennedy, Martin A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Brain; CYP2D6 genotype; Harm avoidance; Novelty seeking; Personality

Indexed keywords

CYTOCHROME P450 2D6; FLUOXETINE; NORTRIPTYLINE;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DEPRESSION; DNA POLYMORPHISM; DOPAMINERGIC SYSTEM; ENZYME METABOLISM; FEMALE; GENE MUTATION; GENOTYPE; HARM AVOIDANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; PERSONALITY DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; SEROTONINERGIC SYSTEM; SOCIAL BEHAVIOR; TEMPERAMENT;

EID: 2142642298     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.20163     Document Type: Article

References (35)

1. Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH. 1996. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nat Genet 12:81-84.
2. Bertilsson L. 1995. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192-209.
3. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D. 1989. Debrisoquine hydroxylation polymorphism and personality. Lancet 1:555.
4. Blairy S, Massat I, Staner L, Le Bon O, Van Gestel S, Van Broeckhoven C, Hilger C, et al. 2000. 5-HT2a receptor polymorphism gene in bipolar disorder and harm avoidance personality trait. Am J Med Genet 96:360-364.
5. Carter JD, Joyce PR, Mulder RT, Luty SE, McKenzie J. 2000. Gender differences in the presentation of depressed outpatients: A comparison of descriptive variables. J Affect Disord 61:59-67.
6. Chinta SJ, Pai HV, Upadhya SC, Boyd MR, Ravindranath V. 2002. Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res Mol Brain Res 103(1-2):49-61.
7. Cholerton S, Daly AK, Idle JR. 1992. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13:434-439.
8. Chomczynski P, Qasba PK. 1984. Alkaline transfer of DNA to plastic membrane. Biochem Biophys Res Commun 122:340-344.
9. Ciulla TA, Sklar RM, Hauser SL. 1988. A simple method for DNA purification from peripheral blood. Anal Biochem 174(2):485-488.
10. Cloninger CR, Svrakic DM, Przybeck TR. 1993. A psychobiological model of temperament and character. Arch Gen Psychiatry 50:975-990.
11. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, et al. 1996. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet 12:78-80.
12. Ebstein RP, Gritsenko I, Nemanov L, Frisch A, Osher Y, Belmaker RH. 1997. No association between the serotonin transporter gene regulatory region polymorphism and the Tridimensional Personality Questionnaire (TPQ) temperament of harm avoidance. Mol Psychiatry 2:224-226.
13. Fonne-Pfister R, Bargetzi MJ, Meyer UA. 1987. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148: 1144-1150.
14. Gebhardt C, Leisch F, Schussler P, Fuchs K, Stompe T, Sieghart W, Hornik K, et al. 2000. Non-association of dopamine D4 and D2 receptor genes with personality in healthy individuals. Psychiatr Genet 10: 131-137.
15. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC, Wolf CR. 1997. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27:111-125.
16. Hiroi T, Imaoka S, Funae Y. 1998. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249:838-843.
17. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, Funae Y. 2001. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142:3901-3908.
18. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. 1996. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355.
19. Jorm AF, Prior M, Sanson A, Smart D, Zhang Y, Easteal S. 2000. Association of a functional polymorphism of the serotonin transporter gene with anxiety-related temperament and behavior problems in children: A longitudinal study from infancy to the mid-teens. Mol Psychiatry 5:542-547.
20. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, Stevens IF. 2002. Patterns and predictors of remission, response, and recovery in major depression treated with fluoxetine or nortriptyline. Aust NZ J Psychiatry 36:384-391.
21. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Sullivan PF, Cloninger RC. 2003. Borderline personality disorder in major depression: Symptomatology, temperament, character, differential drug response, and 6-month outcome. Compr Psychiatry 44:35-43.
22. Kusumi I, Suzuki K, Sasaki Y, Kameda K, Sasaki T, Koyama T. 2002. Serotonin 5-HT(2A) receptor gene polymorphism, 5-HT(2A) receptor function, and personality traits in healthy subjects: A negative study. J Affect Disord 68:235-241.
23. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK. 1998. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529-541.
24. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, et al. 1996. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531.
25. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. 1993. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 87:23-28.
26. Luty SE, Joyce PR, Mulder RT, Sullivan PF, McKenzie JM. 2002. The interpersonal sensitivity measure in depression: Associations with temperament and character. J Affect Disord 70:307-312.
27. Michalets EL. 1998. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84-112.
28. Noble EP, Ozkaragoz TZ, Ritchie TL, Zhang X, Belin TR, Sparkes RS. 1998. D2 and D4 dopamine receptor polymorphisms and personality. Am J Med Genet 81:257-267.
29. Reif A, Lesch KP. 2003. Toward a molecular architecture of personality. Behav Brain Res 139:1-20.
30. Roberts R, Joyce P, Kennedy MA. 2000. Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction. Hum Mutat 16:77-85.
31. Sachse C, Brockmoller J, Bauer S, Roots I. 1997. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295.
32. Samochowiec J, Rybakowski F, Czerski P, Zakrzewska M, Stepien G, Pelka-Wysiecka J, Horodnicki J, et al. 2001. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationship to temperamental dimensions measured by the Temperament And Character Inventory in healthy volunteers. Neuropsychobiology 43:248-253.
33. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. 1995. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215-223.
34. Tsai SJ, Hong CJ, Cheng CY. 2002. Serotonin transporter genetic polymorphisms and harm avoidance in the Chinese. Psychiatr Genet 12:165-168.
35. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ. 2003. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13:173-181.